Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression

@article{Roseman2018QualityOA,
  title={Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression},
  author={Leor Roseman and David J. Nutt and Robin Lester Carhart-Harris},
  journal={Frontiers in Pharmacology},
  year={2018},
  volume={8}
}
Introduction: It is a basic principle of the “psychedelic” treatment model that the quality of the acute experience mediates long-term improvements in mental health. In the present paper we sought to test this using data from a clinical trial assessing psilocybin for treatment-resistant depression (TRD). In line with previous reports, we hypothesized that the occurrence and magnitude of Oceanic Boundlessness (OBN) (sharing features with mystical-type experience) and Dread of Ego Dissolution… Expand
Dose–response relationships of psilocybin-induced subjective experiences in humans
TLDR
Psilocybin intensified almost all characteristics of altered states of consciousness assessed with the given questionnaires, and the results may only apply to controlled laboratory experiments and not to recreational use. Expand
Rediscovering Psilocybin as an Antidepressive Treatment Strategy
TLDR
An overview of the current state of research on the potential mechanisms of psilocybin, its antidepressant potential, and the associated risks and adverse effects is provided to provide an update on a controversial topic discussed in psychopharmacology. Expand
Trial of Psilocybin versus Escitalopram for Depression.
TLDR
This phase 2, double-blind, randomized, controlled trial involving patients with long-standing, moderate-to-severe major depressive disorder did not show a significant difference in antidepressant effects between psilocybin and escitalopram in a selected group of patients. Expand
Study Protocol for “Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study”
TLDR
The results of this pilot study will not only shed light on the acceptability, brain mechanisms, and impression of the potential efficacy of psilocybin as an adjunct treatment for AN but will be essential in shaping a subsequent Randomised Control Trial (RCT) that would test this treatment against a suitable control condition. Expand
Characterization and prediction of acute and sustained response to psychedelic psilocybin in a mindfulness group retreat
TLDR
Meditation seems to enhance psilocybin’s positive effects while counteracting possible dysphoric responses, and the role of emotion/attention regulation in shaping the experiential quality of psychedelic states, as well as the experience of selflessness as a modulator of behavior and attitudes are highlighted. Expand
A potential role for psilocybin in the treatment of obsessive-compulsive disorder
  • E. Jacobs
  • Medicine
  • Journal of Psychedelic Studies
  • 2020
TLDR
Although the current evidence is limited, that multiple signals point in directions consistent with treatment potential, alongside the psychological and physiological safety of clinically administered psilocybin, support the expansion of research, both in animal models and in further randomized controlled trials, to properly investigate this potential. Expand
How does it feel to be on psilocybin? Dose-response relationships of subjective experiences in humans
TLDR
The paper at hand could serve as a general literature citation for the use of psilocybin in experimental and clinical research, especially for the comparison of expected and observed subjective drug experiences. Expand
States and Traits Related to the Quality and Consequences of Psychedelic Experiences
Many individuals experience significant positive psychological change after ingesting psychedelic agents such as psilocybin, LSD, and ayahuasca, but some do not. Such changes appear to be mediated byExpand
The therapeutic potential of microdosing psychedelics in depression
  • K. Kuypers
  • Medicine
  • Therapeutic advances in psychopharmacology
  • 2020
TLDR
While it is yet unclear whether psychedelic microdosing is of therapeutic value for depression, the aforementioned effects on selective processes suggest that low doses of psychedelics could play a role in depression by inducing some kind of cognitive flexibility, which might lead to decreased rumination. Expand
Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
TLDR
The strength of the effect sizes, fast onset, and enduring therapeutic effects of these psychotherapeutic agents encourage further double-blind, placebo-controlled clinical trials assessing them for management of negative mood and depressive symptoms. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 101 REFERENCES
Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study.
TLDR
Preliminary support for the safety and efficacy of psilocybin for treatment-resistant depression is provided and motivates further trials, with more rigorous designs, to better examine the therapeutic potential of this approach. Expand
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
TLDR
Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort. Expand
Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
TLDR
A single-group proof-of-concept study to quantify acute effects of psilocybin in alcohol-dependent participants and to provide preliminary outcome and safety data, providing a strong rationale for controlled trials with larger samples to investigate efficacy and mechanisms. Expand
Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on psychedelic experiences?
TLDR
This review aims to re-evaluate earlier and recent concepts of how psychedelic substances may exert beneficial effects, and summarizes evidence for the relationship between subjective experiences and therapeutic success. Expand
Psychedelics in the treatment of unipolar mood disorders: a systematic review
TLDR
The evidence overall strongly suggests that psychedelics should be re-examined in modern clinical trials for their use in unipolar mood disorders and other non-psychotic mental health conditions. Expand
Psychedelics and the essential importance of context
TLDR
This article highlights the pharmacological mechanisms of classic psychedelics that it is believed render their effects exceptionally sensitive to context, and develops an evidence base for long-held assumptions about the critical importance of context in relation to psychedelic use that can help minimise harms and maximise potential benefits. Expand
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial
TLDR
Psilocybin was associated with enduring anxiolytic and anti-depressant effects in patients with cancer-related psychological distress, sustained benefits in existential distress and quality of life, as well as improved attitudes towards death. Expand
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
TLDR
High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases in quality of life, life meaning, and optimism, and decreases in death anxiety. Expand
The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms
TLDR
Seven Challenging Experience Questionnaire factors provide a phenomenological profile of challenging aspects of experiences with psilocybin that provides a basis for future investigation of predictors and outcomes of challenging experiences with classic hallucinogens. Expand
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
TLDR
When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences, and the ability to occasion such experiences prospectively will allow rigorous scientific investigations of their causes and consequences. Expand
...
1
2
3
4
5
...